JP2022535924A - 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 - Google Patents

腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 Download PDF

Info

Publication number
JP2022535924A
JP2022535924A JP2021572583A JP2021572583A JP2022535924A JP 2022535924 A JP2022535924 A JP 2022535924A JP 2021572583 A JP2021572583 A JP 2021572583A JP 2021572583 A JP2021572583 A JP 2021572583A JP 2022535924 A JP2022535924 A JP 2022535924A
Authority
JP
Japan
Prior art keywords
polypeptide
fab
complex
polypeptide complex
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535924A5 (https=
JPWO2020247871A5 (https=
Inventor
キャンベル，デイビッド
バット，ラメシュ
アール． ディライモンド，トーマス
Original Assignee
ジャナックス セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャナックス セラピューティクス，インク． filed Critical ジャナックス セラピューティクス，インク．
Publication of JP2022535924A publication Critical patent/JP2022535924A/ja
Publication of JP2022535924A5 publication Critical patent/JP2022535924A5/ja
Publication of JPWO2020247871A5 publication Critical patent/JPWO2020247871A5/ja
Priority to JP2025050785A priority Critical patent/JP2025111446A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021572583A 2019-06-06 2020-06-05 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 Pending JP2022535924A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050785A JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858254P 2019-06-06 2019-06-06
US62/858,254 2019-06-06
US202062978662P 2020-02-19 2020-02-19
US62/978,662 2020-02-19
PCT/US2020/036493 WO2020247871A2 (en) 2019-06-06 2020-06-05 Compositions and methods relating to tumor activated t cell engagers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050785A Division JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Publications (3)

Publication Number Publication Date
JP2022535924A true JP2022535924A (ja) 2022-08-10
JP2022535924A5 JP2022535924A5 (https=) 2023-06-09
JPWO2020247871A5 JPWO2020247871A5 (https=) 2023-06-09

Family

ID=73652312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572583A Pending JP2022535924A (ja) 2019-06-06 2020-06-05 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
JP2025050785A Pending JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050785A Pending JP2025111446A (ja) 2019-06-06 2025-03-25 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法

Country Status (6)

Country Link
US (3) US20230220105A1 (https=)
EP (1) EP3980131A4 (https=)
JP (2) JP2022535924A (https=)
KR (1) KR20220052898A (https=)
CN (1) CN114423499A (https=)
WO (2) WO2020247871A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200385440A1 (en) * 2017-12-07 2020-12-10 Janux Therapeutics, Inc. Modified bispecific t cell receptors
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
JP2024518539A (ja) * 2020-04-04 2024-05-01 ジャナックス セラピューティクス，インク． 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
EP4337794A4 (en) * 2021-05-11 2025-07-02 Janux Therapeutics Inc ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4519326A1 (en) * 2022-05-04 2025-03-12 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
KR20250051722A (ko) * 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
CN121443645A (zh) * 2023-05-03 2026-01-30 佳努克斯治疗公司 靶向cd3的肿瘤活化的抗体及其用途
WO2025085855A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
WO2025085862A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523176A (ja) * 2014-07-25 2017-08-17 シトムクス セラピューティクス，インコーポレイティド 抗−ｃｄ３抗体、活性化可能抗−ｃｄ３抗体、多重特異的抗−ｃｄ３抗体、多重特異的活性化可能抗−ｃｄ３抗体、及びそれらの使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031264A1 (en) * 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
BRPI0713421A2 (pt) * 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US20110214199A1 (en) * 2007-06-06 2011-09-01 Monsanto Technology Llc Genes and uses for plant enhancement
AU2008328726B2 (en) * 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
CN104540518A (zh) * 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
CN104271602B (zh) * 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
IL270562B (en) * 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016210447A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
JP7038353B2 (ja) * 2016-04-13 2022-03-18 ヴィヴィア バイオテック，エス．エル エクスビボのｂｉｔｅ活性化ｔ細胞
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
CA3287794A1 (en) * 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20210020903A (ko) * 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523176A (ja) * 2014-07-25 2017-08-17 シトムクス セラピューティクス，インコーポレイティド 抗−ｃｄ３抗体、活性化可能抗−ｃｄ３抗体、多重特異的抗−ｃｄ３抗体、多重特異的活性化可能抗−ｃｄ３抗体、及びそれらの使用方法

Also Published As

Publication number Publication date
US20230220109A1 (en) 2023-07-13
JP2025111446A (ja) 2025-07-30
WO2020247867A3 (en) 2021-02-04
EP3980131A2 (en) 2022-04-13
US20230220105A1 (en) 2023-07-13
KR20220052898A (ko) 2022-04-28
US20240376226A1 (en) 2024-11-14
CN114423499A (zh) 2022-04-29
WO2020247871A3 (en) 2021-01-28
WO2020247867A2 (en) 2020-12-10
WO2020247871A2 (en) 2020-12-10
EP3980131A4 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP2022535924A (ja) 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
US12121527B2 (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP4970258B2 (ja) ヒトインターロイキン−１３に対する抗体およびそれらの使用
US11673949B2 (en) Method of modulating the adrenomedullin (ADM) activity of a patient by administering to the patient an anti-ADM antibody or fragment thereof that specifically binds to mature human ADM
US20230059690A1 (en) Anti-psma antibodies, antibody drug conjugates, and methods of use thereof
US10202441B2 (en) Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
US20140294826A1 (en) Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
US20210206844A1 (en) Anti-FSTL3 Antibodies And Uses Thereof
WO2019129214A1 (zh) 针对破伤风毒素的全人源单克隆中和抗体及其应用
JP2021504695A (ja) リガンド−薬物複合体を分析するための酸媒介アッセイ
EP3753579A1 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
KR20140090295A (ko) T 세포 특이적인 인간화 단일조각항체 전달체
HK40073760A (en) Compositions and methods relating to tumor activated t cell engagers
WO2025078534A1 (en) Cd248 inhibitors and uses thereof
WO2025209486A1 (en) Antibodies targeting il-13 and tslp and uses thereof
O'Leary Alternative Antimicrobial Agents Against Multidrug-Resistant Gram-Negative Bacteria
HK40082763A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
WO2023231877A1 (zh) 抗cd228抗体及其药物偶联物
CN121419990A (zh) 用于中和抗原的组合物和方法
박선영 Development of anti-cotinine antibody & its application to EIA and carrier for cotinine-conjugated molecule

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515